Results 21 to 30 of about 1,271,708 (300)

In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs.

PLoS ONE, 2012
Telomerase is a specialized reverse transcriptase responsible for the de novo synthesis of telomeric DNA repeats. In addition to its established reverse transcriptase and terminal transferase activities, recent reports have revealed unexpected cellular ...
Kyle R Hukezalie, Naresh R Thumati, Hélène C F Côté, Judy M Y Wong   +3 more
doaj   +1 more source

The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance

Scientifica, 2012
The use of highly active antiretroviral therapy (HAART) involves combinations of drugs to achieve maximal virological response and reduce the potential for the emergence of antiviral resistance.
Mark A. Wainberg
doaj   +1 more source

Docking Study of HIV-1 Reverse Transcriptase (HIV-1 RT) with Well-Known Nucleoside Reverse Transcriptase Inhibitors (NRTIs) [PDF]

Journal of Advanced Pharmacy Research
Objectives: The nucleic acid-binding cleft in HIV-1 reverse transcriptase (HIV-1 RT) is essential because of its interactions with the polymerase and RNase H active sites. Studying its binding sites for nucleoside reverse transcriptase inhibitors (NRTIs)
Roohallah Yousefi
doaj   +1 more source

A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads [PDF]

, 2006
Background. Our objective was to compare the rate of viral rebound and therapy failure in patients receiving abacavir or efavirenz as the third drug ( in addition to 2 non-abacavir nucleosides) in combination antiretroviral therapy ( cART) and to compare
Phillips, AN, L. Sighinolfi, D'ARMINIO MONFORTE A, R. Cauda, MOIOLI MC, Monforte, AD, COZZI-LEPRI A, DI GIAMBENEDETTO S, M. Mena, Sighinolfi, L, SIGHINOLFI L, A. Cozzi Lepri, Lichtner, M, ICoNA Study Group, Arlotti, M, M. Lichtner, Bongiovanni, M, Mena, M, M. Arlotti, UCSC Roma HIV Cohort Study Group, CAUDA R, A. N. Phillips, De Luca, A, Di Giambenedetto, S, Cozzi-Lepri, A, DE LUCA A, BONGIOVANNI M, PHILLIPS AN, UCSC-Roma HIV Cohort Study Grp, Narciso, P, Cauda, R, IMIT Study Grp, IMIT Study Group, A. De Luca, ICoNA Study Grp, MENA M, ARLOTTI M, NARCISO P, LICHTNER M, M. C. Moioli, Moioli, MC, S. Di Giambenedetto, P. Narciso, M. Bongiovanni, A. d’Arminio Monforte   +44 more
core   +1 more source

High-resolution view of HIV-1 reverse transcriptase initiation complexes and inhibition by NNRTI drugs

Nature Communications, 2021
Initiation of HIV-1 reverse transcription occurs at the host tRNALys 3, which forms a complex with the 5’ end of the HIV-1 viral RNA and reverse transcriptase (RT).
Betty Ha, Kevin P. Larsen, Jingji Zhang, Ziao Fu, Elizabeth Montabana, Lynnette N. Jackson, Dong-Hua Chen, Elisabetta Viani Puglisi   +7 more
doaj   +1 more source

Prevalence of genotypic HIV-1 drug resistance in Thailand, 2002

Annals of Clinical Microbiology and Antimicrobials, 2003
Background The prices of reverse transcriptase (RT) inhibitors in Thailand have been reduced since December 1, 2001. It is expected that reduction in the price of these inhibitors may influence the drug resistance mutation pattern of HIV-1 among infected
Watitpun Chotip, Jenwitheesuk Ekachai, Vibhagool Asda, Chantratita Wasun   +3 more
doaj   +1 more source

Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors.

PLoS ONE, 2020
BackgroundChoice of initial antiretroviral therapy regimen may help children with HIV maintain optimal, continuous therapy. We assessed treatment-naïve children for differences in time to treatment disruption across randomly-assigned protease inhibitor ...
Dwight E Yin, Christina Ludema, Stephen R Cole, Carol E Golin, William C Miller, Meredith G Warshaw, Ross E McKinney, PENPACT-1 (PENTA 9 / PACTG 390) Study Team   +7 more
doaj   +1 more source

Hepatotoxicity of Contemporary Antiretroviral Drugs: A Review and Evaluation of Published Clinical Data

Cells, 2021
Contemporary antiretroviral agents afford enhanced potency and safety for patients living with HIV. Newer antiretroviral drugs are often better tolerated than those initially approved in the early stages of the HIV epidemic.
Ashley O. Otto, Christina G. Rivera, John D. Zeuli, Zelalem Temesgen   +3 more
doaj   +1 more source

Methoxyflavones from as HIV-1 Reverse Transcriptase Inhibitors

Natural Product Communications, 2017
Methoxyflavones are flavonoid widely distributed in plants and has been reported as potent antitumor agents and some of them have shown activity against HIV-1. In this work, two methoxyflavones isolated from Marcetia taxifolia were evaluated in vitro and
Joseph T Ortega, María Luisa Serrano, Alírica I Suárez, Jani Baptista, Flor H Pujol, Héctor R Rangel   +5 more
doaj   +1 more source

HIV-1 Resistance to Islatravir/Tenofovir Combination Therapy in Wild-Type or NRTI-Resistant Strains of Diverse HIV-1 Subtypes

Viruses, 2023
Tenofovir disoproxil fumarate (TDF) and islatravir (ISL, 4′-ethynyl-2-fluoro-2′-deoxyadensine, or MK-8591) are highly potent nucleoside reverse transcriptase inhibitors. Resistance to TDF and ISL is conferred by K65R and M184V, respectively. Furthermore,
Maria E. Cilento, Xin Wen, Aaron B. Reeve, Obiaara B. Ukah, Alexa A. Snyder, Ciro M. Carrillo, Cole P. Smith, Kristin Edwards, Claudia C. Wahoski, Deborah R. Kitzler, Eiichi N. Kodama, Hiroaki Mitsuya, Michael A. Parniak, Philip R. Tedbury, Stefan G. Sarafianos   +14 more
doaj   +1 more source